Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine.

BACKGROUND:Increases in pneumococcal meningitis were reported from Ghanaian regions that lie in the meningitis belt in 2016-2017, despite introduction of 13-valent pneumococcal conjugate vaccine (PCV13) in 2012 using a 3-dose schedule (6, 10, and 14 weeks). We describe pneumococcal meningitis epidem...

Full description

Bibliographic Details
Main Authors: Catherine H Bozio, Abass Abdul-Karim, John Abenyeri, Braimah Abubakari, Winfred Ofosu, Justina Zoya, Mahamoudou Ouattara, Velusamy Srinivasan, Jeni T Vuong, David Opare, Franklin Asiedu-Bekoe, Fernanda C Lessa
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6128537?pdf=render
id doaj-a44b338b589b48e3bf30498bb572e83f
record_format Article
spelling doaj-a44b338b589b48e3bf30498bb572e83f2020-11-25T02:01:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01139e020320510.1371/journal.pone.0203205Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine.Catherine H BozioAbass Abdul-KarimJohn AbenyeriBraimah AbubakariWinfred OfosuJustina ZoyaMahamoudou OuattaraVelusamy SrinivasanJeni T VuongDavid OpareFranklin Asiedu-BekoeFernanda C LessaBACKGROUND:Increases in pneumococcal meningitis were reported from Ghanaian regions that lie in the meningitis belt in 2016-2017, despite introduction of 13-valent pneumococcal conjugate vaccine (PCV13) in 2012 using a 3-dose schedule (6, 10, and 14 weeks). We describe pneumococcal meningitis epidemiology in the Ghanaian Northern and Upper West regions across two meningitis seasons. METHODS:Suspected meningitis cases were identified using World Health Organization standard definitions. Pneumococcal meningitis was confirmed if pneumococcus was the sole pathogen detected by polymerase chain reaction, culture, or latex agglutination in cerebrospinal fluid collected from a person with suspected meningitis during December 2015-March 2017. Pneumococcal serotyping was done using PCR. Annual age-specific pneumococcal meningitis incidence (cases per 100,000 population) was calculated, adjusting for suspected meningitis cases lacking confirmatory testing. FINDINGS:Among 153 pneumococcal meningitis cases, 137 (89.5%) were serotyped; 100 (73.0%) were PCV13-type, including 85 (62.0%) that were serotype 1, a PCV13-targeted serotype. Persons aged ≥5 years accounted for 96.7% (148/153) of cases. Comparing 2015-2016 and 2016-2017 seasons, the proportion of non-serotype 1 PCV13-type cases decreased from 20.0% (9/45) to 4.1% (3/74) (p = 0.008), whereas the proportion that was serotype 1 was stable (71.1% (32/45) vs. 58.1% (43/74); p = 0.16). Estimated adjusted pneumococcal meningitis incidence was 1.8 in children aged <5 years and ranged from 6.8-10.5 in older children and adults. CONCLUSIONS:High pneumococcal meningitis incidence with a large proportion of serotype 1 disease in older children and adults suggests infant PCV13 vaccination has not induced herd protection with this schedule in this high-transmission setting.http://europepmc.org/articles/PMC6128537?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Catherine H Bozio
Abass Abdul-Karim
John Abenyeri
Braimah Abubakari
Winfred Ofosu
Justina Zoya
Mahamoudou Ouattara
Velusamy Srinivasan
Jeni T Vuong
David Opare
Franklin Asiedu-Bekoe
Fernanda C Lessa
spellingShingle Catherine H Bozio
Abass Abdul-Karim
John Abenyeri
Braimah Abubakari
Winfred Ofosu
Justina Zoya
Mahamoudou Ouattara
Velusamy Srinivasan
Jeni T Vuong
David Opare
Franklin Asiedu-Bekoe
Fernanda C Lessa
Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine.
PLoS ONE
author_facet Catherine H Bozio
Abass Abdul-Karim
John Abenyeri
Braimah Abubakari
Winfred Ofosu
Justina Zoya
Mahamoudou Ouattara
Velusamy Srinivasan
Jeni T Vuong
David Opare
Franklin Asiedu-Bekoe
Fernanda C Lessa
author_sort Catherine H Bozio
title Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine.
title_short Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine.
title_full Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine.
title_fullStr Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine.
title_full_unstemmed Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine.
title_sort continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in ghana five years after introduction of 13-valent pneumococcal conjugate vaccine.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description BACKGROUND:Increases in pneumococcal meningitis were reported from Ghanaian regions that lie in the meningitis belt in 2016-2017, despite introduction of 13-valent pneumococcal conjugate vaccine (PCV13) in 2012 using a 3-dose schedule (6, 10, and 14 weeks). We describe pneumococcal meningitis epidemiology in the Ghanaian Northern and Upper West regions across two meningitis seasons. METHODS:Suspected meningitis cases were identified using World Health Organization standard definitions. Pneumococcal meningitis was confirmed if pneumococcus was the sole pathogen detected by polymerase chain reaction, culture, or latex agglutination in cerebrospinal fluid collected from a person with suspected meningitis during December 2015-March 2017. Pneumococcal serotyping was done using PCR. Annual age-specific pneumococcal meningitis incidence (cases per 100,000 population) was calculated, adjusting for suspected meningitis cases lacking confirmatory testing. FINDINGS:Among 153 pneumococcal meningitis cases, 137 (89.5%) were serotyped; 100 (73.0%) were PCV13-type, including 85 (62.0%) that were serotype 1, a PCV13-targeted serotype. Persons aged ≥5 years accounted for 96.7% (148/153) of cases. Comparing 2015-2016 and 2016-2017 seasons, the proportion of non-serotype 1 PCV13-type cases decreased from 20.0% (9/45) to 4.1% (3/74) (p = 0.008), whereas the proportion that was serotype 1 was stable (71.1% (32/45) vs. 58.1% (43/74); p = 0.16). Estimated adjusted pneumococcal meningitis incidence was 1.8 in children aged <5 years and ranged from 6.8-10.5 in older children and adults. CONCLUSIONS:High pneumococcal meningitis incidence with a large proportion of serotype 1 disease in older children and adults suggests infant PCV13 vaccination has not induced herd protection with this schedule in this high-transmission setting.
url http://europepmc.org/articles/PMC6128537?pdf=render
work_keys_str_mv AT catherinehbozio continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
AT abassabdulkarim continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
AT johnabenyeri continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
AT braimahabubakari continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
AT winfredofosu continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
AT justinazoya continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
AT mahamoudououattara continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
AT velusamysrinivasan continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
AT jenitvuong continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
AT davidopare continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
AT franklinasiedubekoe continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
AT fernandaclessa continuedoccurrenceofserotype1pneumococcalmeningitisintworegionslocatedinthemeningitisbeltinghanafiveyearsafterintroductionof13valentpneumococcalconjugatevaccine
_version_ 1724958494221664256